CPHI Japan 2023, taking place from April 19-21, offers an unparalleled platform for exploring the significant implications of China’s rapidly growing biopharma sector on the Asia-Pacific (APAC) region. Ian Haydock, Editor-In-Chief, Insights, Asia-Pacific at Citeline, will deliver a keynote address discussing the expanding influence of China’s biopharma industry on the region’s innovation, manufacturing, and outsourcing dynamics.
In honor of its 20th anniversary, CPHI Japan 2023 will host an array of special events, including an award ceremony celebrating the critical role of companies in the development of Japan’s thriving pharmaceutical industry. With 7,000 executives from 95 countries expected to participate, the event is set to return to pre-pandemic levels of engagement.
China’s strategic shift toward Southeast Asia and Japan, driven by recent setbacks in the US market, is reshaping the global biopharma landscape and fueling the development of new distribution channels and regional manufacturing hubs. Japan’s innovation environment remains strong but faces challenges from drug pricing systems that impact research-based multinationals operating in the country.
As China’s share of global R&D in new drugs and vaccines reaches 24%, the country’s influence on the APAC region’s biopharma sector is substantial. The APAC biopharma industry, characterized by a diverse range of smaller innovators, engenders a dynamic supply side with numerous supply partners.